Current definitions insufficient for interpreting clinical outcomes
By Joseph P. Iannotti, MD, PhD and Eric Ricchetti, MD
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The Walch classification is the most frequently utilized method for defining glenohumeral pathology in osteoarthritis. Orthopaedic surgeons have used it to make recommendations for surgical interventions and joint replacements since its creation nearly a decade ago. However, many studies have demonstrated Walch’s lower inter-rater reliability in classifying pathology, which leaves room for error in performing and interpreting clinical studies. The Walch classification’s inability to reproduce common patterns of pathology becomes even more apparent when treating patients with more severe glenoid pathology.
We hypothesized that the problem is not with the overall classification method, but with its existing definitions. Specifically, some patterns of glenoid bone loss and humeral head alignment do not fit within existing Walch definitions. These pathologies have distinguishable patterns of bone erosion and alignment that require different treatment and produce unique clinical outcomes.
This need for a more reproducible classification is especially important for patients with B and C glenoid types. Additionally, an enhanced classification system is crucial for consistent clinical outcomes research involving glenohumeral pathology. Define these new pathologies, and Walch becomes a more reliable classification system.
We analyzed 155 cases of nontraumatic, noninflammatory, primary glenohumeral osteoarthritis. We used a custom software to evaluate preoperative 3D computer tomography (CT) and to examine the relationship of the center of the humeral head to the center of the glenoid as well as the patterns of glenoid morphology.
We assessed premorbid glenohumeral anatomy based on previously validated methods using 3D glenoid vault and humeral sphere models, including joint line, premorbid glenoid version and humeral-glenoid alignment (HGA). We measured pathologic glenohumeral anatomy as joint line medialization, paleo glenoid length, glenoid version and HGA.
Consensus readings by two surgeons determined classifications for the cases within the existing five Walch groups. We then reclassified each patient based on the methods above.
We discovered measurable and reproducible anatomic features that differentiate new glenoid morphologic types from the existing Walch stratifications.
B3 has both central and asymmetric posterior bone loss making the joint line more medialized. Unlike B2, B3 either does not have or has an incredibly small paleo glenoid.
C2 and B2 both have a biconcave surface with associated posterior humeral head subluxation. However, the pathologic glenoid retroversion and the premorbid glenoid vault model version are both significantly higher in C2 than B2.
The B3 and C2 patterns are distinct and may result in different clinical outcomes than their B2 or C counterparts. B3 and C2 should be included in a new or modified Walch classification with seven different glenoid subtypes. We recommend further independent use of a modified classification that adds the B3 and C2 groups to Walch. These new definitions will help determine whether these pathologies require different surgical interventions for optimal recovery.
Mean values for pathologic glenoid version, premorbid version, length of the paleo glenoid, joint line medialization, pathologic humeral-glenoid alignment (HGA), and premorbid HGA. For a given measure, p values represent significant differences in means across all the glenoid subtypes in the modified classification. Post hoc tests (with Bonferroni multiple comparison corrections) were then conducted to identify specific glenoid subtypes showing differences on pairwise comparisons.
Dr. Iannotti is Chair of the Orthopaedic and Rheumatologic Institute. Dr. Ricchetti is staff in the Department of Orthopaedic Surgery.
Center will coordinate, interpret and archive imaging data for all multicenter trials conducted by the foundation’s Osteoarthritis Clinical Trial Network
Leading-edge technology will improve diagnosis and prognosis
What we typically see in these atypical cases
Pioneering techniques eliminate pain, restore mobility
Researchers hope it may one day help patients avoid explantation surgery
Rest is often not the best care for gamers’ overuse injuries
Biologic approaches, growing implants and more
Study reports zero infections in nearly 300 patients